A study to evaluate isavuconazonium sulfate for the treatment of invasive aspergillosis (IA) or invasive mucormycosis (IM) in pediatric participants

Trial Identifier: 9766-CL-0107
Sponsor: Astellas Pharma Global Development, Inc.
Start Date: August 2019
Primary Completion Date: December 2022
Study Completion Date: December 2022
Condition: Infections - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
Belgium Gent, Belgium, 9000
Belgium Leuven, Belgium, 3000
Spain Barcelona, Spain, 8035
Spain Madrid, Spain, 28009
Spain Madrid, Spain, 28041
United States of America, CA Los Angeles, CA, United States of America, 90095
United States of America, CA Los Angeles, CA, United States of America, 90027
United States of America, CA Orange, CA, United States of America, 92868
United States of America, DC Washington, DC, United States of America, 20010
United States of America, IL Chicago, IL, United States of America, 60611